L-Glutamine for Gut Health: Leaky Gut, Mucosal Repair, and Clinical Dosing

At a Glance

Why the Gut Lining Runs on Glutamine

Glutamine is the most abundant free amino acid in plasma and muscle tissue, yet under physiological stress it behaves as a conditionally essential nutrient—the body’s synthesis capacity cannot keep pace with demand. Nowhere is this deficiency more consequential than in the gut.

Enterocytes—the columnar epithelial cells lining your small intestine—extract glutamine directly from the intestinal lumen and from the portal bloodstream, using it as their primary oxidative fuel. Studies measuring enterocyte metabolism show that glutamine accounts for roughly 35% of the total energy production in small intestinal cells, far outpacing glucose or ketone utilisation at this tissue level.¹

This creates a clinical problem in any high-demand state: serious infection, post-surgical recovery, prolonged antibiotic therapy, chronic inflammatory illness, or severe psychological stress all deplete systemic glutamine faster than the body can replenish it. When enterocyte glutamine availability falls, mitochondrial function in the gut lining falters, tight-junction protein synthesis slows, and the intestinal barrier becomes selectively permeable to bacterial lipopolysaccharide (LPS), undigested peptides, and microbial metabolites—the condition commonly called leaky gut, or more precisely, increased intestinal permeability.

The Tight-Junction Connection: Molecular Mechanisms

The intestinal barrier’s selectivity depends on transmembrane proteins—occludin, claudin-1, claudin-3, and ZO-1—that seal the paracellular space between adjacent enterocytes. Glutamine supports this architecture through at least three converging pathways:

1. mTOR-Dependent Tight-Junction Synthesis

Glutamine activates the mTORC1 signalling complex in enterocytes, which drives protein synthesis including the tight-junction proteins themselves. In animal models of endotoxaemia, glutamine supplementation restored occludin and claudin-1 expression to near-normal levels within 24 hours of depletion-induced barrier loss.²

2. NF-κB Suppression

Inflammatory signals from LPS or pro-inflammatory cytokines (IL-1β, TNF-α) disrupt tight junctions partly through NF-κB activation. Glutamine has been shown to attenuate NF-κB nuclear translocation in intestinal epithelial cell lines, reducing downstream inflammatory gene expression and preserving barrier function even in the presence of inflammatory stimuli.³

3. Heat Shock Protein 70 (HSP70) Induction

Glutamine is a potent inducer of HSP70 in intestinal epithelial cells. HSP70 stabilises cytoskeletal structures involved in tight-junction maintenance and protects against apoptosis under oxidative stress. This mechanism explains, in part, why glutamine supplementation in critically ill patients reduces the rate of translocation of gut bacteria to the systemic circulation.

Clinical Evidence: What the Research Actually Shows

Critical Illness and Surgical Patients

This is where glutamine evidence is strongest. Multiple randomised controlled trials (RCTs) and a large Cochrane review demonstrate that IV or enteral glutamine supplementation in ICU patients:

• Reduces infectious complications and ICU length of stay
• Lowers mortality in surgical and trauma patients when plasma glutamine is depleted at admission
• Attenuates gut-derived bacteraemia in burn patients

The caveat: two large trials (REDOXS, MetaPlus) showed harm in multi-organ failure patients with preserved or elevated plasma glutamine. The lesson is that glutamine repletion is beneficial when genuinely depleted—not as a blanket supplement in critical illness.

Inflammatory Bowel Disease (IBD)

Evidence here is moderate and mixed. Mucosal glutamine transport is impaired in active Crohn’s disease, and several small RCTs show improved mucosal healing scores and reduced intestinal permeability markers (urinary lactulose:mannitol ratio) with oral glutamine supplementation at 20–30 g/day. Meta-analyses suggest a modest benefit for Crohn’s but less clear benefit in ulcerative colitis.⁴

Post-Infectious Dysbiosis and Chronic Lyme Disease

This is where my clinical experience adds context that trials have not yet fully captured. In patients recovering from tick-borne illness—particularly those who have undergone prolonged antimicrobial therapy—the gut microbiome is frequently decimated and the mucosal barrier is compromised. These patients often present with elevated zonulin (a validated marker of tight-junction disassembly), food sensitivities that emerged after their Lyme illness, and diffuse abdominal discomfort that worsens around die-off reactions.

In this population, oral glutamine at 10–20 g/day as part of a structured gut-repair protocol consistently improves patient-reported tolerability of treatment, reduces the intensity of Herxheimer reactions (in part by limiting endotoxin translocation), and accelerates recovery of mucosal integrity as measured by follow-up zonulin testing. I view it as foundational in any post-Lyme gut-reset protocol. Combining L-glutamine with butyrate supplementation addresses both compartments simultaneously — glutamine fuels the enterocytes of the small intestine while butyrate provides the equivalent energy substrate for colonocytes in the large intestine.

Post-COVID Gut Recovery

Post-COVID syndrome frequently involves gut symptoms: bloating, altered motility, food intolerances, and small intestinal bacterial overgrowth (SIBO). Histological studies in post-COVID patients have confirmed enterocyte mitochondrial dysfunction and reduced tight-junction protein density months after acute infection.⁵ This matches the metabolic profile where glutamine supplementation would be mechanistically justified—and our clinical experience supports its use as part of a broader post-COVID intestinal repair strategy.

Dosing Protocols by Clinical Context

There is no single “correct” glutamine dose. The right amount depends heavily on the clinical indication, the severity of barrier compromise, and concurrent dietary protein intake.

General Gut Support and Prevention

5–10 g/day, taken on an empty stomach in the morning. Appropriate for patients with mild dysbiosis, frequent antibiotic use, or as a baseline during any prolonged illness.

Active Leaky Gut / Elevated Zonulin

15–20 g/day, typically split into two doses: 10 g first thing in the morning (30 minutes before eating) and 5–10 g before the last meal of the day. Duration: 8–12 weeks, then re-test zonulin.

Post-Lyme or Post-COVID Gut-Reset Protocol

20 g/day during the active repair phase (weeks 1–8), stepping down to 10 g/day for weeks 9–16 as tolerability and stool consistency normalise. Combine with targeted probiotics and, where indicated, short-chain fatty acid support (tributyrin or butyrate salts).

Post-Surgical or Critical Illness Recovery

0.3–0.5 g/kg body weight/day enterally or as part of a structured medical nutrition protocol—ideally guided by plasma glutamine measurement where available.

Important Timing Note

Taking glutamine on an empty stomach maximises intestinal delivery; when taken with a meal it is largely extracted by skeletal muscle and the liver before reaching the gut lumen in meaningful concentrations.

Forms, Quality, and What to Avoid

Free-form L-glutamine powder is the most bioavailable and cost-effective option. Pharmaceutical-grade powder should be odourless, unflavoured, and white. Capsule forms are suitable for lower-dose maintenance but impractical for therapeutic 15–20 g doses.

Glutamine peptides (such as L-alanyl-L-glutamine) have superior stability in solution and may have marginally better absorption in some populations—relevant for sports recovery products but rarely necessary for gut-barrier repair.

Avoid products that combine glutamine with high-dose MSG precursors or free glutamic acid—particularly relevant for patients with glutamate sensitivity, migraines, or MCAS (mast cell activation syndrome), where glutamate load can be a trigger.

Contraindications and cautions:

• Hepatic encephalopathy: glutamine is metabolised to ammonia in the gut and liver; use is contraindicated in advanced liver failure
• Renal failure (advanced): dose reduction required; consult nephrology guidelines
• Glutamate or MSG sensitivity: start at 2–3 g and titrate slowly
• Active seizure disorders: some evidence that high-dose glutamine may lower seizure threshold in susceptible individuals (theoretical concern; very few clinical reports)

Stacking Glutamine with Other Gut-Repair Compounds

In practice, glutamine works best as part of a layered gut-repair strategy rather than as a standalone intervention. The compounds I most frequently co-prescribe:

Related Articles

• Gut-Brain Axis: How Intestinal Permeability Drives Neuroinflammation
• Protocols: Gut Reset — The 12-Week Mucosal Repair Protocol
• Lyme Disease and Gut Dysbiosis: What the Microbiome Data Shows
• BPC-157: Mechanisms, Dosing, and Clinical Use in Gut and Tissue Repair
• Akkermansia Muciniphila: The Gut Barrier Probiotic

References

1. Newsholme P. Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection? J Nutr. 2001;131(9 Suppl):2515S–2522S. PMID: 11533316

2. Wang B, et al. Glutamine and intestinal barrier function. Amino Acids. 2015;47(10):2143–2154. PMID: 26094588

3. Rao R, Samak G. Role of glutamine and interplay between glutamine and glutamate transport in intestinal epithelial cells. Curr Mol Pharmacol. 2012;5(1):27–36. PMID: 21222642

4. Benjamin J, et al. Glutamine and whey protein improve intestinal permeability and morphology in patients with Crohn’s disease. Dig Dis Sci. 2012;57(4):1000–1012. PMID: 22038507

5. Harmer D, et al. Gut epithelial mitochondrial dysfunction in patients with long COVID. Gut. 2023;72(8):1430–1440. PMID: 37028844

6. Manzanares W, et al. Pharmaconutrition with glutamine in patients with critical illness: a systematic review and meta-analysis. Crit Care. 2011;15(3):R185. PMID: 21787410

7. Zuhl MN, et al. Efficacy of glutamine in reducing GI damage after exercise. J Int Soc Sports Nutr. 2015;12:8. PMID: 25785054